BioRestorative Therapies Inc
$ 1.12
-5.88%
26 Dec - close price
- Market Cap 9,941,400 USD
- Current Price $ 1.12
- High / Low $ 1.20 / 1.06
- Stock P/E N/A
- Book Value 0.28
- EPS -1.46
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.90 %
- ROE -2.08 %
- 52 Week High 2.55
- 52 Week Low 0.98
About
BioRestorative Therapies Inc. (BRTX), headquartered in Melville, New York, is a pioneering entity in the field of regenerative medicine, focusing on the advancement of cutting-edge therapies utilizing adult stem cell technology. The company is dedicated to addressing critical unmet medical needs through safe and effective treatments, with a particular emphasis on orthopedic and neurological applications. BRTX's innovative approach to cellular and tissue-based methodologies underscores its potential to significantly influence healthcare solutions, establishing the company as an essential contributor in the rapidly evolving landscape of regenerative medicine.
Analyst Target Price
$13.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-18 | 2025-08-12 | 2025-05-12 | 2025-03-31 | 2024-11-11 | 2024-08-13 | 2024-06-11 | 2024-03-18 | 2023-11-13 | 2023-08-11 | 2023-05-12 | 2023-03-27 |
| Reported EPS | -0.33 | -0.3 | -0.64 | -0.375 | -0.0068 | -0.5 | -0.33 | -0.57 | -0.65 | -0.77 | -1.53 | -1.19 |
| Estimated EPS | -0.375 | -0.38 | -0.34 | -0.5533 | -0.43 | -0.56 | -0.52 | -0.69 | -0.68 | -1.19 | -1.26 | -1.43 |
| Surprise | 0.045 | 0.08 | -0.3 | 0.1783 | 0.4232 | 0.06 | 0.19 | 0.12 | 0.03 | 0.42 | -0.27 | 0.24 |
| Surprise Percentage | 12% | 21.0526% | -88.2353% | 32.2248% | 98.4186% | 10.7143% | 36.5385% | 17.3913% | 4.4118% | 35.2941% | -21.4286% | 16.7832% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: BRTX
2025-12-10 22:09:21
BioRestorative Therapies (OTCMKTS:BRTXQ) saw its shares drop by 2.7% on Tuesday, with a significantly lower trading volume compared to its average. The company, which develops adult stem-cell therapies for disc/spine and metabolic disorders, has its stock trading below key moving averages, indicating a bearish trend. Despite its current analyst rating as "Hold," MarketBeat recommends exploring other highly-rated stocks.
2025-11-17 12:13:00
BioRestorative Therapies, Inc. has scheduled a Type B meeting with the FDA in mid-December to discuss an accelerated Biologics License Application (BLA) approval pathway for BRTX-100, its treatment for chronic lumbar disc disease (cLDD). The company plans to present positive safety and efficacy data from its ongoing Phase 2 clinical trial and request an expedited timeline for commencing a Phase 3 trial. BRTX-100 has already received FDA Fast Track designation, which aims to accelerate the development and review of treatments for serious conditions with unmet medical needs.
2025-11-17 05:21:14
BioRestorative Therapies (BRTX) reported a significant revenue drop in Q3 2025 to $11,800 from $233,600 and an increased net loss per share of $3.03. Despite financial setbacks, the company is advancing its BRTX-100 clinical trials for chronic lumbar disc disease, which has fast-track FDA designation, and expanding its biocosmeceutical business. BioRestorative remains optimistic about future growth through strategic initiatives including potential accelerated FDA approval and new commercial leadership.
2025-11-16 17:04:52
BioRestorative Therapies experienced a challenging quarter with decreased revenue and wider losses, but Wall Street analysts maintain an optimistic outlook. This optimism is fueled by anticipated FDA approvals, a rebound in the BioCosmeceutical business, and successful new fundraising efforts. Analysts are largely recommending a 'buy' with a median 12-month price target of $8, signaling confidence in the company's future growth despite short-term setbacks.
2025-11-14 08:15:00
BioRestorative Therapies, Inc. held its Q3 2025 earnings call, reporting revenues of $11,800, a net loss of $3 million, and ending the quarter with $4.5 million in cash. The company highlighted progress in its BRTX-100 clinical trial for chronic lumbar disc disease, which received Fast Track designation, and discussed the growing potential of its biocosmeceuticals business and ThermoStem metabolic program. Lance Alstodt also noted the near completion of enrollment for the Phase II BRTX-100 trial and ongoing discussions for a ThermoStem licensing agreement.
2025-11-12 16:05:00
BioRestorative Therapies reported Q3 2025 results with $11,800 in revenue and a net loss of $3.0 million, or $0.33 per share. The company ended the quarter with $4.5 million in cash and marketable securities and subsequently raised approximately $1.085 million gross through a registered direct offering. Key business updates include Fast Track designation for BRTX-100, a Japanese Notice of Allowance for the ThermoStem platform, and the appointment of a new Head of Global Commercial Operations.
